EUCTR2006-003843-22-IT进行中（未招募）不适用
prospeCtive study on intensive early rheumatoid arthritis treatment with adalimUmab: induction of REmission and maintenance - 'CURE'A Phase IV multicenter, randomized, double-blind study
OSPEDALE POLICLINICO S. MATTEO0 个研究点开始时间: 2006年8月30日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Able and willing to give written informed consent and comply with the requirements of the study protocol.
- •2. Patients with active rheumatoid arthritis diagnosed for at least 6 weeks, but no more than 1 year, according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of rheumatoid arthritis
- •3. Patients naïve to treatment with MTX and that have received a prednisone dose ≤ 7,5 mg/d and a total prednisone dose ≤250 mg .
- •4. Swollen joint count (SJC) > 8 (66 joint count), and tender joint count (TJC) > 8 (68 joint count) at screening and baseline.
- •5. At screening CRP > 1.5 mg/dL (15 mg/L) or ESR ≥ 28 mm/h
- •6. ≥ 1 joint erosion or RF positivity or anti-CCP positivity
- •7. Age 18-70 years.
- •8. Use of NSAIDs is permitted if stable for at least 2 weeks prior to baseline.
- •9. For patients of reproductive potential (males and females), use of a reliable means of contraception (e.g. hormonal contraceptive, patch, intrauterine device, physical barrier) throughout study participation.
- •10. Must be willing to receive oral folate.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusions related to RA
- •1.Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis or Felty's syndrome). Secondary Sjögren's syndrome or secondary limited cutaneous vasculitis with RA is permitted.
- •2.Functional class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis.
- •3.History of, or current, inflammatory joint disease other than RA (including, but not limited to, gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (including, but not limited to, systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or any overlap syndrome).
- •Exclusions Related to General Health
- •1.Any surgical procedure, including bone/joint surgery/synovectomy (including joint fusion or replacement) within 12 weeks prior to baseline or planned during the study.
- •2.Pregnancy or breastfeeding.
- •3.Significant and/or uncontrolled cardiac or pulmonary disease (including obstructive pulmonary disease).
- •4.Evidence of significant concomitant disease, including but not limited to, nervous system, renal, hepatic, endocrine or gastrointestinal disorders which, in the investigator's opinion, would preclude patient participation.
- •5.Primary or secondary immunodeficiency (history of, or currently active), including known history of HIV infection.
- •6.Known active infection of any kind, or any major episode of infection requiring hospitalization or treatment with i.v.anti-infectives within 4 weeks of baseline or completion of oral anti-infectives within 2 weeks prior to baseline.
- •7.History of serious recurrent or chronic infection.
- •8.History of previously untreated infection with mycobacterium tuberculosis or current treatment for it.
- •**Latent TB infection is defined as:
- •- a positive Mantoux Purified Protein Derivative (PPD) skin test using 10 IU of PPD (≥ 5 mm induration, regardless of BCG vaccination status)
- •- chest radiograph with changes suggestive for TB infection (a chest radiograph will be performed at screening if not performed within 6 weeks prior to screening).
- •These patients should be treated accordingly to local guidelines before entering the study.
- •9.History of cancer, including solid tumors, hematologic malignancies and carcinoma in situ (except basal cell and squamous cell carcinoma of the skin that have been excised and cured).
- •10.Any neurological (congenital or acquired), vascular or systemic disorder which could affect any of the efficacy assessments, in particular, joint pain and swelling (e.g.Parkinsons disease, cerebral palsy, diabetic neuropathy
- •11.Any history or presence of congestive heart failure (CHF) (New York Heart Association classification for CHF: Class III or IV).
- •12.Any history of myocardial infarction within 5 years.
- •13.Cardiac arrhythmia or clinically significant electrocardiogram (ECG) abnormality, such as ischemia.
- •14.Currently active alcohol or drug abuse or history of alcohol or drug abuse within 24 weeks prior to baseline.
- •Exclusions Related to Medications
- •1.History of a severe allergic or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of adalimimab or methotrexate.
- •2.Previous treatment with MTX
- •3.Intra-articular or parenteral glucocorticoids within 4 weeks prior to baseline.
研究者
相似试验
招募中
不适用
Orencia Clinical study in Early rheumatoid Arthritis using New criteria(Efficacy and safety of MTX therapy and Abatacept/MTX combination therapy in early RA patients in daily clinical practice retrospective observation study.)Rheumatoid ArthritisJPRN-UMIN000011019School of Medicine, Keio University75
已完成
不适用
Study of the Treatment of Algerian Patients With Early Rheumatoid ArthritisRheumatoid ArthritisNCT02008266Hoffmann-La Roche532
进行中（未招募）
1 期
REMission INDuction in very early Rheumatoid ArthritisEUCTR2015-004858-17-NLniversity Medical Center Utrecht (UMCU)267
已完成
4 期
REMission INDuction in very early Rheumatoid ArthritisRAArthritis10013361NL-OMON47431niversitair Medisch Centrum Utrecht267
进行中（未招募）
1 期
Remission Induction in Very Early Rheumatoid Arthritis (RIVERA):a comparison of etanercept plus methotrexate plus steroid with standard therapy - RIVERAEUCTR2006-001428-38-GBniversity Hospitals Birmingham NHS Foundation Trust20